Genmab — Oktober 2019

[Solsen]

Ere der Poc på den alternative sc tilgang, som Sanofi prøver ?

[Sukkeralf]

Nej Elektrofi er et meget nyt selskab, så ny teknologi der vist aldrig er ap
røvet i klinikken endnu

[lahn1]

JW har ved flere lejligheder henvist til JNJ bud på at SC kan stå for så meget som 80% af salget fra start. De 80% indgår såvel i Halozyme's forecast på Enhanze
https://medwatch.dk/Medicinal___Biotek/article11213918.ece

[Solsen]

Tak - så lidt vej endnu.

[Bulder]

Tak lahn1. Den mindes jeg ikke at have set før. Så genmab havde regnet med (håbet på) PR for sc. Ligner et spm til q&a.

[Sukkeralf]

Uanset om der er PR eller ej bør vi vel snart få en PDUFA dato

[Bulder]

Har spurgt Andrew Carlsen

[Bulder]

... som svarede: Ikke endnu men en fair antagelse er standard review på 10 måneder fra den 12 juli fa ansøgning blev indsendt.

[Bulder]

Så vi taler om 12. april.

[Sukkeralf]

Det er vel også ok trods alt

[Bulder]

8 mdrs fuld fart på sc i 2020 er fint nok.

[Bulder]

Det giver jo klinikkerne 4 mdr mere at øve sig i, så vi accellererer hurtigere

[bikube]

Bulder - du er herligt optimistisk - med lidt småfejl. Juli + 10mdr. er altså maj, ikke april

[Bulder]

øv, jeg havde ellers lige talt på fingrene

[E_L]

coincidental Should we treat smoldering myeloma? A debate https://twitter.com/VincentRK/status/1187397174226837504

[Helge_LarsenPI-redaktør]

Apropos yesterday.

[Bulder]

I remember some time ago, we had a debate about this subject. The cause was a minor conflict between haema deps at Danish hospitals on the background of some statistical numbers, that showed that Vejle Sygehus had a better MM-survival than the others. The reason for this was not that Vejle was any "better", but that they started treatment earlier - already in the (high-risk) smoldering phase - and thus got a better survival statistics. Maybe they should give Plesner a call for some advice.

[Solsen]

Yes and one of the replies says “as long as we have no cure of the disease” he is supporting “no” early treatment (smoldering). We could argue that if we should have a chance to cure it should be with early intervention.

[Helge_LarsenPI-redaktør]

Meet Genmab A/S CEO Jan van de Winkel in an online interactive Q&A session about the company and its Q3 Report.

8th of November 16.30 CET . Tilmelding: https://www.proinvestor.com/index.php?p=q-and-a&groupid=107

[Helge_LarsenPI-redaktør]

Meet Oncology Venture CFO Henrik Moltke in an online interactive Q&A session about the company and its Q3 Report.
6th of November 16.00 CET. https://www.proinvestor.com/index.php?p=q-and-a&groupid=110